Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention

TLDR:

• Amgen’s Q3 revenue hits $9.6B, with 12% growth year-over-year.
• Strong sales from Repatha® and TEPEZZA® boost Amgen’s performance.
• Amgen reports 25% increase in operating income for Q3 2025.
• Q3 free cash flow rises to $4.2B, marking a significant improvement.
• Amgen expects robust growth, with 2025 revenues forecasted between $35.8B-$36.6B.

Amgen Inc. (AMGN) experienced a notable uptick in its stock price, closing at $296.70, reflecting a modest 0.13% gain.

Amgen Inc., AMGN

The company’s performance in the third quarter of 2025 has drawn attention with a 12% increase in total revenues. With strong product sales and a solid cash flow, Amgen’s robust financial results set a positive tone for future growth.

Strong Revenue Growth and Product Sales Performance

Amgen’s total revenues for Q3 2025 reached $9.6 billion, a 12% increase compared to the previous year. This growth was primarily driven by a 14% increase in volume across its product lines. However, a 4% reduction in net selling prices partially offset the positive trend. Sixteen products posted double-digit sales growth, including key brands such as Repatha and TEPEZZA, reflecting solid demand across various therapeutic areas.

The company’s revenue growth highlights the strength of its portfolio in diverse markets, from oncology to inflammation. Particularly, Repatha® (evolocumab) saw a 40% increase in sales, reaching $794 million. TEPEZZA® (teprotumumab-trbw) also performed strongly, posting a 15% rise, bolstered by higher inventory levels and a favorable pricing strategy. These figures demonstrate the company’s ability to leverage its innovative products for sustained growth.

Operating Income and Cash Flow Surge

Amgen’s GAAP operating income rose by 25%, reaching $2.5 billion, driven by higher revenues and improved operating margins. This translates into a significant increase in operating margin, which improved by 2.5 percentage points, now standing at 27.6%. Non-GAAP operating income increased 8%, totaling $4.3 billion, though the non-GAAP operating margin saw a slight decline to 47.1%.

Cash flow generation also demonstrated a positive trend, with Amgen generating $4.2 billion in free cash flow during the third quarter. This is a marked improvement from the $3.3 billion in the same period last year. The company attributed this increase to favorable working capital changes and lower interest payments, offsetting higher capital expenditures. The surge in cash flow underpins the company’s ongoing ability to fund growth and return to shareholders.

Forward-Looking Outlook and Financial Guidance

For the full year 2025, Amgen expects total revenues to range between $35.8 billion and $36.6 billion. The company forecasts GAAP earnings per share (EPS) to be between $13.76 and $14.60. On a non-GAAP basis, EPS is expected to be between $20.60 and $21.40, signaling strong growth potential moving forward. These projections take into account the impact of existing tariffs but exclude any potential future changes in pricing or tariffs.

Amgen’s leadership, under CEO Robert A. Bradway, has emphasized the company’s focus on expanding access to its medicines and advancing innovative treatments. With a strong portfolio, disciplined investment strategies, and a growing pipeline, Amgen is well-positioned to sustain long-term growth. As the company moves forward, investors will closely monitor how Amgen continues to navigate the competitive landscape and further capitalize on its diverse product offerings.

The post Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention appeared first on CoinCentral.